NASDAQ:GENE

Genetic Technologies Stock Forecast, Price & News

$3.66
+0.10 (+2.81 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.50
▼
$3.72
50-Day Range
$3.37
▼
$4.54
52-Week Range
$2.77
▼
$8.18
Volume289,590 shs
Average Volume289,817 shs
Market Capitalization$56.29 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49
30 days | 90 days | 365 days | Advanced Chart
Receive GENE News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.


Genetic Technologies logo

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Headlines

Analyzing Genetic Technologies (NASDAQ:GENE) & Kodiak Sciences (NASDAQ:KOD)
Analyzing Genetic Technologies (NASDAQ:GENE) & Kodiak Sciences (NASDAQ:KOD)
July 25, 2021 |  americanbankingnews.com
The Association of American Physicians and Surgeons (AAPS) Asks: How Do We Know the Effects of the Genetic Technology behind COVID Vaccines?
The Association of American Physicians and Surgeons (AAPS) Asks: How Do We Know the Effects of the Genetic Technology behind COVID Vaccines?
July 22, 2021 |  finance.yahoo.com
Luck of the draw: How the random results of the genetic lottery can influence a host of your lifes outcomes
Luck of the draw: How the random results of the genetic lottery can influence a host of your life's outcomes
July 20, 2021 |  msn.com
Genetic Technologies Acquires EasyDNA To Expand Into Wellness Testing
Genetic Technologies Acquires EasyDNA To Expand Into Wellness Testing
July 19, 2021 |  finance.yahoo.com
New UW clinic to use latest genetic technology to help patients with unknown diseases
New UW clinic to use latest genetic technology to help patients with unknown diseases
July 19, 2021 |  msn.com
Genetic Technologies (NASDAQ:GENE) Stock Passes Above 200-Day Moving Average of $0.00
Genetic Technologies (NASDAQ:GENE) Stock Passes Above 200-Day Moving Average of $0.00
July 13, 2021 |  americanbankingnews.com
Genetic Technologies (NASDAQ:GENE) Stock Crosses Above Two Hundred Day Moving Average of $0.00
Genetic Technologies (NASDAQ:GENE) Stock Crosses Above Two Hundred Day Moving Average of $0.00
July 3, 2021 |  americanbankingnews.com
Genetic Technologies Gets U.S. Patent for Genomic Analysis
Genetic Technologies Gets U.S. Patent for Genomic Analysis
June 11, 2021 |  marketwatch.com
US Patent Office Grants Foundational Pharmacogenomic Patent
US Patent Office Grants Foundational Pharmacogenomic Patent
June 11, 2021 |  finance.yahoo.com
Infinity BiologiX, Genetic Technologies and Vault Heath launch new test to assess severity of COVID-19 in individuals
Infinity BiologiX, Genetic Technologies and Vault Heath launch new test to assess severity of COVID-19 in individuals
June 9, 2021 |  ca.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.38 out of 5 stars

Medical Sector

3743rd out of 4,434 stocks

Biological Products, Except Diagnostic Industry

393rd out of 424 stocks

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions

What stocks does MarketBeat like better than Genetic Technologies?

Wall Street analysts have given Genetic Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genetic Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Genetic Technologies' next earnings date?

Genetic Technologies is scheduled to release its next quarterly earnings announcement on Monday, August 30th 2021.
View our earnings forecast for Genetic Technologies.

How has Genetic Technologies' stock price been impacted by Coronavirus?

Genetic Technologies' stock was trading at $2.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GENE stock has increased by 55.1% and is now trading at $3.66.
View which stocks have been most impacted by COVID-19.

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the following people:
  • Mr. Stanley Sack, Chief Operating Officer (Age 57, Pay $238.61k)
  • Dr. Richard Allman, Chief Scientific Officer (Age 61, Pay $141.1k)
  • Dr. Jerzy Muchnicki MBBS, Chief Medical Officer & Exec. Director (Age 64, Pay $114.78k)
  • Mr. Simon Morriss, Chief Exec. Officer
  • Mr. Michael Tonroe B.Sc., F.C.A., M.A.I.C.D., Bsc(Hons), ACA, MAICD, Chief Financial Officer (Age 54)
  • Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, Consultant
  • Mr. Justyn Stedwell, Company Sec. (Age 40)

Who are some of Genetic Technologies' key competitors?

Some companies that are related to Genetic Technologies include ADMA Biologics (ADMA), Cabaletta Bio (CABA), Elevation Oncology (ELEV), Cardiff Oncology (CRDF), Miromatrix Medical (MIRO), CASI Pharmaceuticals (CASI), Freeline Therapeutics (FRLN), Genfit (GNFT), Fennec Pharmaceuticals (FENC), Applied Genetic Technologies (AGTC), Ayala Pharmaceuticals (AYLA), Champions Oncology (CSBR), X4 Pharmaceuticals (XFOR), Axcella Health (AXLA) and LogicBio Therapeutics (LOGC).
View all of GENE's competitors.

What other stocks do shareholders of Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Therapeutics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX).

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

How do I buy shares of Genetic Technologies?

Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $3.66.

How much money does Genetic Technologies make?

Genetic Technologies has a market capitalization of $56.29 million and generates $10,000.00 in revenue each year.

What is Genetic Technologies' official website?

The official website for Genetic Technologies is www.gtgcorporate.com.

Where are Genetic Technologies' headquarters?

Genetic Technologies is headquartered at 60-66 HANOVER STREET, FITZROY C3, 3065.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 011-61-3-8412-7000 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.